These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33356712)

  • 1. Liposomal doxorubicin-related palmar-plantar erythrodysesthesia (hand-foot syndrome): a case report.
    Ni C; Fang J; Qian H; Xu Q; Shen F
    J Int Med Res; 2020 Dec; 48(12):300060520974854. PubMed ID: 33356712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).
    Templeton AJ; Ribi K; Surber C; Sun H; Hsu Schmitz SF; Beyeler M; Dietrich D; Borner M; Winkler A; Müller A; von Rohr L; Winterhalder RC; Rochlitz C; von Moos R; Zaman K; Thürlimann BJ; Ruhstaller T;
    Breast; 2014 Jun; 23(3):244-9. PubMed ID: 24656636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.
    Miolo G; Baldo P; Bidoli E; Lombardi D; Scalone S; Sorio R; Veronesi A
    Tumori; 2009; 95(6):687-90. PubMed ID: 20210230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
    Charalambous A; Tsitsi T; Astras G; Paikousis L; Filippou E
    Eur J Oncol Nurs; 2021 Feb; 50():101866. PubMed ID: 33227569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia.
    Lopez AM; Wallace L; Dorr RT; Koff M; Hersh EM; Alberts DS
    Cancer Chemother Pharmacol; 1999; 44(4):303-6. PubMed ID: 10447577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
    Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
    Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised controlled feasibility trial to evaluate Lawsonia inermis (henna)'s effect on palmar-plantar erythrodysesthesia induced by capecitabine or pegylated liposomal doxorubicin.
    Stavrinou M; Tsitsi T; Astras G; Paikousis L; Charalambous A
    Eur J Oncol Nurs; 2021 Apr; 51():101908. PubMed ID: 33626423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.
    Webster-Gandy JD; How C; Harrold K
    Eur J Oncol Nurs; 2007 Jul; 11(3):238-46. PubMed ID: 17350337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hand-foot syndrome induced by chemotherapy drug: Case series study and literature review.
    Zaiem A; Hammamia SB; Aouinti I; Charfi O; Ladhari W; Kastalli S; Aidli SE; Lakhoua G
    Indian J Pharmacol; 2022; 54(3):208-215. PubMed ID: 35848692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case series of docetaxel-induced dorsal hand-foot syndrome.
    Patel J; Ringley JT; Moore DC
    Ther Adv Drug Saf; 2018 Aug; 9(8):495-498. PubMed ID: 30364883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serious stomatitis and esophagitis: a peculiar mucous reaction induced by pegylated liposomal doxorubicin.
    Ma H; Chen M; Liu J; Li Y; Li J
    An Bras Dermatol; 2015; 90(3 Suppl 1):209-11. PubMed ID: 26312719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.
    Ajgal Z; Chapuis N; Emile G; Cessot A; Tigaud JM; Huillard O; Boudou-Rouquette P; Fontenay M; Goldwasser F; Alexandre J
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1033-9. PubMed ID: 26420236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A variant of the chemotherapy-associated erythrodysesthesia syndrome related to high-dose cyclophosphamide.
    Matsuyama JR; Kwok KK
    DICP; 1989 Oct; 23(10):776, 778-9. PubMed ID: 2815854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distal phalange necrosis: a severe manifestation of palmar plantar erythrodysesthesia.
    Palaia I; Angioli R; Bellati F; Basile S; Rabitti C; Panici PB
    Am J Obstet Gynecol; 2006 Oct; 195(4):e1-2. PubMed ID: 16875651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience.
    Rossi D; Catalano G
    Oncology; 2007; 73(3-4):277-8. PubMed ID: 18424894
    [No Abstract]   [Full Text] [Related]  

  • 16. Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer.
    Bun S; Yunokawa M; Tamaki Y; Shimomura A; Shimoi T; Kodaira M; Shimizu C; Yonemori K; Fujiwara Y; Makino Y; Terakado H; Tamura K
    Support Care Cancer; 2018 Jul; 26(7):2161-2166. PubMed ID: 29372396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
    Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
    Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn.
    Markman M; Kulp B; Peterson G
    Gynecol Oncol; 2004 Aug; 94(2):578-80. PubMed ID: 15297208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin: a retrospective study.
    Zhao Y; Su W; Liang G; Shan X; Ma W; Tang D; Li L; Niu X; Zhao S; Zhang Q; Zhao W
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):63. PubMed ID: 34696815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
    Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO
    Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.